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Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) re-
ceptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized
seizures, and for primary generalized tonic–clonic seizures in patients with epilepsy aged ≥12 years. Perampanel
was recently approved for monotherapy use for focal seizures in the U.S.A. Anti-seizure drug monotherapy may
be preferable to polytherapy, which is generally associated with increased toxicity, non-compliance, and cost.
Here, we report cases where patients had converted to perampanel monotherapy during open-label extension
(OLEx) portions of 9 Phase II and III studies.
Of 2245 patientswho enrolled in theOLEx studies,we identiﬁed7 patientswith drug-resistant focal seizureswho
discontinued all non-perampanel anti-seizure drugs and were maintained on perampanel monotherapy for
≥91 days until the end of data cut-off. Patients received perampanel monotherapy for up to 1099 days
(157 weeks), most at a modal dose of 12 mg. Seizure data were available for 6 patients, of whom 5 had a ≥90%
reduction in overall seizure frequency between baseline and their last 13-week period of monotherapy (3
were seizure-free). Perampanel monotherapy was generally well tolerated and the safety proﬁle during
perampanel monotherapy was consistent with clinical and post-marketing experience in the adjunctive setting.
This analysis included a small proportion of patients with highly drug-resistant focal seizures who converted to
monotherapy during OLEx studies. While these limited data are encouraging in suggesting that perampanel
might be useful as a monotherapy, further studies are required to explore outcomes in a less drug-resistant pop-
ulation, where a larger proportion of patients might beneﬁt from monotherapy.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is ap-
proved for adjunctive treatment of focal seizures, with or without sec-
ondarily generalized (SG) seizures, and for primary generalized tonic–
clonic seizures in patients with epilepsy aged ≥12 years [1,2].
Perampanel was recently approved for monotherapy use for focal sei-
zures in the U.S.A.
It has been a regulatory standard for anti-seizure drugs to be initially
evaluated for adjunctive use, given ethical concerns around the use of
placebo-controlled trials for anti-seizure drug monotherapy [3].
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However, since anti-seizure drug polytherapy is often associated with
increased toxicity, non-adherence, and cost, monotherapy may be pref-
erable in some clinical practice settings [4].
Despite challenges in trial design, many anti-seizure drugs have
demonstrated efﬁcacy as monotherapies [5]. In the U.S.A., several anti-
seizure drugs have had their original indications expanded to include
use inmonotherapy settings, including lacosamide, lamotrigine extend-
ed release, and topiramate. Furthermore, the arguments of a white
paper has recently advocated a uniﬁed indication for anti-seizure
drugs, irrespective of concomitant anti-seizure drug use [3], and as a
consequence, the Food and Drug Administration (FDA) has determined
that it is acceptable to extrapolate data from adjunctive trials to the
monotherapy setting.
Here, we report data from patients who converted to perampanel
monotherapy during the open-label extension (OLEx) portions of
Phase II and Phase III adjunctive studies. This analysis explores our un-
derstanding around the conversion to perampanel monotherapy for
the treatment of focal seizures. In addition, and based on the FDA policy
around extrapolation of adjunctive data to the monotherapy setting,
these data formed part of the data that were submitted to the FDA,
supporting the approval of perampanel monotherapy in the U.S.A. for
the treatment of focal seizures (with or without SG seizures) in patients
with epilepsy aged ≥12 years [2,6]. These data have also been submitted
to the European Medicines Agency as part of the data in support of an
amendment to the perampanel Summary of Product Characteristics to in-
clude monotherapy data in the Clinical Section.
2. Methods
The clinical development of perampanel as an adjunctive treatment
included 9 Phase II and III studies in patients receiving 1–3 concomitant
anti-seizure drugs. Eight were randomized, double-blind, placebo-con-
trolled studies in patients with drug-resistant focal seizures, with or
without SG seizures (Studies 206 [NCT00144690] and 208
[NCT00416195]: patients aged 18–70 years; Studies 304
[NCT00699972], 305 [NCT00699582], 306 [NCT00700310], and 335
[NCT01618695]: patients aged ≥12 years; and Study 235
[NCT01161524]: adolescent patients aged ≥12 to ≤17 years) [7–11], or
primary generalized tonic–clonic seizures and idiopathic generalized
epilepsy (Study 332 [NCT01393743]: patients aged ≥12 years) [12].
The remaining study was an open-label, dose-escalation Phase II study
of adjunctive perampanel as an oral suspension in patients from the
U.S.A. aged 2 to b12 years with any seizure type (Study 232
[NCT01527006]).
All studies were performed in accordance with the Declaration of
Helsinki, European Medicines Agency requirements, the U.S. Code of
Federal Regulations, and the ICH-E6 Guideline for GoodClinical Practice.
All participants gave written informed consent.
Patients who completed 1 of these studies could receive adjunctive
perampanel (daily dose of up to 12 mg) in 1 of the following OLEx
studies:
○ Study 207 (patients enrolled from Studies 206 and 208; n = 138)
[13]
○ Study 307 (patients enrolled from Studies 304, 305, and 306; n =
1218) [14]
○ Study 335 OLEx (n= 596)
○ Study 235 OLEx (n= 114)
○ Study 332 OLEx (n= 138)
○ Study 232 OLEx (n= 41).
In all OLEx studies, concomitant anti-seizure drugs could be adjusted
in dose or changed as clinically dictated (e.g., removed if seizures were
well controlled with perampanel). Therefore, although perampanel
monotherapy was not an objective, it was a possibility if all non-
perampanel anti-seizure drugs were discontinued.
This analysis included patients who discontinued all non-
perampanel anti-seizure drugs during 1 of the OLEx studies, received
perampanel as monotherapy for at least 91 days, and were able to con-
tinue monotherapy thereafter (until the relevant data cut-off date for
each individual OLEx study). The time period of 91 days was selected
with the aim of identifying cases where there was a clear decision to at-
tempt conversion to monotherapy and to exclude cases where non-
perampanel anti-seizure drugs were temporarily discontinued over a
shorter period of time for any other reason (e.g., due to tolerability rea-
sons or patient non-adherence). Throughout the studies, median per-
cent change in seizure frequency per 28 days from pre-perampanel
baseline was assessed and patients were monitored for treatment-
emergent adverse events (TEAEs).
3. Results
3.1. Patients
Overall, 2245 patients with drug-resistant seizures, despite treat-
ment with 1–3 concomitant anti-seizure drugs, were enrolled in the
OLEx studies. Of these, 9 patients discontinued all concomitant anti-sei-
zure drugs and took perampanel as monotherapy for at least 91 days.
Of these 9 patients, 7 continued to receive perampanel as monother-
apy until data cut-off, and so met the criteria for inclusion in the present
analysis. Six of these patients had received perampanel monotherapy in
Study 307 (Patients 1–6), and 1 in the Study 235 OLEx (Patient 7). Five
patients had received placebo in the double-blind treatment phase of
the Core Study (Patients 1, 3, 4, 6, and 7) and 2 had received a non-effec-
tive dose of perampanel 2mg (Patients 2 and 5), although all received an
optimized perampanel dose in the OLEx studies. At baseline of the dou-
ble-blind treatment phase, patients had been receiving 1 concomitant
anti-seizure drug (Patients 3, 4, 5, and 7), 2 concomitant anti-seizure
drugs (Patients 1 and 6), or 3 concomitant anti-seizure drugs (Patient 2).
The 7 patients comprised 1 female and 6 male patients, with an age
range of 15–40 years. At baseline of the double-blind treatment phase,
time since diagnosis of epilepsy ranged from 2.8 to 21.9 years, and sei-
zure frequency per 28 days ranged from 0.5 to 93.8. Three patients
had been experiencing focal seizures with motor signs (Patients 3, 4,
and 5), 1 had been experiencing focal seizures without motor signs (Pa-
tient 1), 2 had been experiencing focal seizures with secondary general-
ization (Patients 4 and 6), and 5 had been experiencing focal impaired
awareness seizures (complex partial seizures in the previous ILAE clas-
siﬁcation; Patients 1, 2, 5, 6, and 7).
The other 2 patients, who received perampanel monotherapy for
91 days, later reverted back to polytherapy (reasons for discontinuation
of perampanel monotherapy unknown); these patients were not in-
cluded in the analysis because they did not meet the pre-deﬁned re-
quirement for monotherapy to have continued until data cut-off. One
of these patients was a 58-year-old female who received perampanel
for 1126 days in Study 307, including 123 days as monotherapy
(modal daily dose = 12 mg); during the only 13-week window where
monotherapy was received throughout (Weeks 79–91 of perampanel
treatment), this patient had a 68.4% reduction in seizure frequency com-
pared with baseline. The other patient was a 6-year-old female who re-
ceived perampanel for 287 days in the Study 232 OLEx, including
103 days as monotherapy (modal daily dose = 0.2 mg/kg); during the
only 13-week window where monotherapy was received throughout
(Weeks 27–39 of perampanel treatment), this patient had an 87.7% re-
duction in seizure frequency compared with baseline.
3.2. Perampanel treatment
Fig. 1 summarizes the time courses of treatment with perampanel
and concomitant anti-seizure drugs in Patients 1–7. Patients received
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perampanel monotherapy for up to 1099 days (157 weeks), most at a
modal dose of 12 mg. The duration of treatment and modal doses for
the individual patients were: Patient 1—594 days (excluding 1 day of
rescue medication with levetiracetam 500 mg in Week 15), modal
dose = 12 mg; Patient 2—345 days, modal dose = 12 mg; Patient
3—203 days, modal dose = 12 mg; Patient 4—1099 days, modal dose
= 4 mg; Patient 5—273 days, modal dose = 12 mg; Patient
6—409 days, modal dose = 12 mg; and Patient 7—181 days, modal
dose = 8 mg.
Concomitant anti-seizure drugs included an enzyme-inducing anti-
seizure drug in 2 patients (Patient 4, oxcarbazepine; Patient 6, carba-
mazepine). Concomitant anti-seizure drugs were generally down-
titrated gradually (valproic acid in Patients 1, 3, and 5; zonisamide
and lamotrigine in Patient 2; carbamazepine in Patient 6; levetiracetam
in Patient 7), although they were discontinued abruptly in some cases
(levetiracetam in Patient 1; valproic acid in Patient 2; oxcarbazepine
in Patient 4; topiramate in Patient 6; see Fig. 1 for full details).
3.3. Changes in seizure frequency
Fig. 2 shows changes in seizure frequency for the 6 patients in
Study 307. At their last 13-week time window, 5 of these patients
had at least a 90% reduction in seizure frequency compared with
baseline (Patients 2–5), with 3 of these achieving complete seizure
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freedom (Patients 2, 5, and 6). The other patient had a 49.7% reduction
in seizure frequency (Patient 1).
For patients with focal impaired awareness seizures or SG seizures at
baseline, therewere reductions of N90% in the frequency of these seizure
types throughout perampanel monotherapy (focal impaired awareness
seizures: Patients 1, 2, 5, and 6; SG seizures: Patients 4 and 6).
Full seizure data were unavailable for the patient in the Study 235
OLEx (Patient 7), although it was reported that this patient did not ex-
perience any seizures over the ﬁnal 6 months of the study, after
converting to monotherapy.
3.4. Tolerability
Five patients experienced TEAEs during perampanel monotherapy;
no TEAEs occurred in more than 1 patient. There were no deaths and
only 1 serious TEAE (Patient 4; colitis), which was not considered to
be related to perampanel treatment.
The most common class of TEAEs observed was psychiatric disor-
ders, which were experienced by 2 patients. The psychiatric disorders
reported during the studieswere irritability,mood swings, nervousness,
and panic attack (all n= 1).
4. Discussion
Here, we report data from patients who converted to perampanel
monotherapy during the OLEx portions of Phase II and Phase III studies
of perampanel. These data may reﬂect certain clinical practices, as dos-
ing was more ﬂexible in the OLEx portion of these studies than in the
double-blind treatment phases, with daily perampanel dose titrated to
a maximum of 12 mg and adjustment of concomitant anti-seizure
drugs permitted.
Of the 2245 patients with drug-resistant seizures, despite treatment
with 1–3 concomitant anti-seizure drugs, who enrolled in the OLEx
studies, 7 patients, all with focal seizures (with or without SG seizures),
converted to perampanel monotherapy. In most cases, concomitant
anti-seizure drugs were down-titrated gradually, however, they were
also stopped abruptly in some cases. The duration of perampanelmono-
therapy treatment was relatively long at up to 1099 days (N3 years),
and most patients received perampanel at a modal dose of 12 mg. The
limited analysis suggested that the patients generallymaintained a sim-
ilar, or numerically better, level of seizure control during perampanel
monotherapy than during prior adjunctive perampanel treatment. Fur-
thermore, perampanel monotherapy appeared to be well tolerated,
with no TEAE occurring in more than 1 patient and no drug-related se-
rious TEAEs. The safety proﬁle during perampanel monotherapy was
consistent with clinical and post-marketing experience in the adjunc-
tive setting, and no unique TEAEs were observed.
As the OLEx studies were not placebo controlled, a major limitation
is that the seizure reductions could have been due to spontaneous im-
provements in the state of the disease rather than perampanel treat-
ment. This has previously been suggested in a study of patients with
drug-resistant epilepsy in which 27/225 (12%) patients became sei-
zure-free for at least 12 months following anti-seizure drug treatment
[15]. Of these patients, a new anti-seizure drug had been added within
3 months of remission in 13 cases, a dose had been changed but no
anti-seizure drug added in 7 cases, and in 7 cases there was neither a
new anti-seizure drug nor dose change during the previous 3 months,
suggesting that the state of the disease in these patients improvedwith-
out any intervention [15]. This is further supported by a matched, pro-
spective study that reported seizure outcomes following anti-seizure
drug switching in both seizure-free and non-seizure-free patients with
focal epilepsy [16]. Among patients who had not been seizure-free dur-
ing the previous 6 months, 10/27 (37.0%) patients who switched to a
different anti-seizure drug became seizure-free at 6 months compared
with 15/27 (55.6%) patients who remained on the same anti-seizure
drug [16]. There was no evidence to suggest that changes in drug
therapy led to improvements in seizure control in the non-seizure-
free patients, thereby suggesting that improvements in seizure control
in some drug-resistant patients may be spontaneous rather than due
to therapeutic alterations [16]. Similar results were also observed in
an earlier mixed, prospective–retrospective study [17]. Indeed, such
ﬂuctuations between seizure freedom and seizure relapse have been
observed during long-term follow-up in 1/6 adults with newly diag-
nosed epilepsy [18]. Nonetheless, the 7 patients who received
perampanelmonotherapy in the current studies were identiﬁed as hav-
ing highly drug-resistant epilepsy, and it has previously been suggested
that the likelihood of achieving seizure freedom decreases once a pa-
tient is identiﬁed as drug-resistant [15,18]. For example, in a previous
study of 1098 untreated patients, 49.5% of patients taking their ﬁrst
anti-seizure drug regimen (all were taking monotherapy) were sei-
zure-free at the time of their last follow-up visit (median follow-up of
7.5 years); however, of those patients taking a second anti-seizure
drug regimen (n=398), 36.7% became seizure-free (25.4% were taking
monotherapy and 11.3% were taking combination therapy), and of
those taking a third anti-seizure drug regimen (n=168) only 24.4% be-
came seizure-free (15.5% were taking monotherapy and 8.9% were tak-
ing combination therapy). The probability of seizure freedom continued
to decrease with each successive drug regimen [18]. In addition, pa-
tients who took perampanel monotherapy for b91 days, or who
attempted to withdraw concomitant anti-seizure drugs but failed to
do so, were not included. Better-designed studies may be informative
in speciﬁcally examining perampanel use in this setting, and helping
to identify the patient populations most likely to beneﬁt, before any
ﬁrm conclusions are drawn.
This analysis included a small proportion of patients with highly
drug-resistant focal seizures who converted to treatment with
perampanel monotherapy during OLEx studies. While these limited
data are encouraging in suggesting that perampanel might be useful
as a monotherapy, further studies are required to explore outcomes in
a less drug-resistant population, where a larger proportion of patients
might beneﬁt from monotherapy.
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